Modeling the Novel SERD Elacestrant in Cultured Fulvestrant-Refractory HR-Positive Breast Circulating Tumor Cells

The authors analyzed clinical outcomes with elacestrant, compared with endocrine therapy, among women who had previously been treated with a fulvestrant-containing regimen from the recent Phase III EMERALD Study.